Prevalence and risk factors for lung involvement on low-dose chest CT (LDCT) in a paucisymptomatic population of 247 patients affected by COVID-19.

COVID-19 Pneumonia Quantitative evaluation Tomography X-ray computed

Journal

Insights into imaging
ISSN: 1869-4101
Titre abrégé: Insights Imaging
Pays: Germany
ID NLM: 101532453

Informations de publication

Date de publication:
17 Nov 2020
Historique:
received: 04 09 2020
accepted: 30 10 2020
entrez: 17 11 2020
pubmed: 18 11 2020
medline: 18 11 2020
Statut: epublish

Résumé

Low-dose chest CT (LDCT) showed high sensitivity and ability to quantify lung involvement of COVID-19 pneumopathy. The aim of this study was to describe the prevalence and risk factors for lung involvement in 247 patients with a visual score and assess the prevalence of incidental findings. For 12 days in March 2020, 250 patients with RT-PCR positive tests and who underwent LDCT were prospectively included. Clinical and imaging findings were recorded. The extent of lung involvement was quantified using a score ranging from 0 to 40. A logistic regression model was used to explore factors associated with a score ≥ 10. A total of 247 patients were analyzed; 138 (54%) showed lung involvement. The mean score was 4.5 ± 6.5, and the mean score for patients with lung involvement was 8.1 ± 6.8 [1-31]. The mean age was 43 ± 15 years, with 121 males (48%) and 17 asymptomatic patients (7%). Multivariate analysis showed that age > 54 years (odds ratio 4.4[2.0-9.6] p < 0.001) and diabetes (4.7[1.0-22.1] p = 0.049) were risk factors for a score ≥ 10. Multivariate analysis including symptoms showed that only age > 54 years (4.1[1.7-10.0] p = 0.002) was a risk factor for a score ≥ 10. Rhinitis (0.3[0.1-0.7] p = 0.005) and anosmia (0.3[0.1-0.9] p = 0.043) were protective against lung involvement. Incidental imaging findings were found in 19% of patients, with a need for follow-up in 0.6%. The prevalence of lung involvement was 54% in a predominantly paucisymptomatic population. Age ≥ 55 years and diabetes were risk factors for significant parenchymal lung involvement. Rhinitis and anosmia were protective against LDCT abnormalities.

Sections du résumé

BACKGROUND BACKGROUND
Low-dose chest CT (LDCT) showed high sensitivity and ability to quantify lung involvement of COVID-19 pneumopathy. The aim of this study was to describe the prevalence and risk factors for lung involvement in 247 patients with a visual score and assess the prevalence of incidental findings.
METHODS METHODS
For 12 days in March 2020, 250 patients with RT-PCR positive tests and who underwent LDCT were prospectively included. Clinical and imaging findings were recorded. The extent of lung involvement was quantified using a score ranging from 0 to 40. A logistic regression model was used to explore factors associated with a score ≥ 10.
RESULTS RESULTS
A total of 247 patients were analyzed; 138 (54%) showed lung involvement. The mean score was 4.5 ± 6.5, and the mean score for patients with lung involvement was 8.1 ± 6.8 [1-31]. The mean age was 43 ± 15 years, with 121 males (48%) and 17 asymptomatic patients (7%). Multivariate analysis showed that age > 54 years (odds ratio 4.4[2.0-9.6] p < 0.001) and diabetes (4.7[1.0-22.1] p = 0.049) were risk factors for a score ≥ 10. Multivariate analysis including symptoms showed that only age > 54 years (4.1[1.7-10.0] p = 0.002) was a risk factor for a score ≥ 10. Rhinitis (0.3[0.1-0.7] p = 0.005) and anosmia (0.3[0.1-0.9] p = 0.043) were protective against lung involvement. Incidental imaging findings were found in 19% of patients, with a need for follow-up in 0.6%.
CONCLUSION CONCLUSIONS
The prevalence of lung involvement was 54% in a predominantly paucisymptomatic population. Age ≥ 55 years and diabetes were risk factors for significant parenchymal lung involvement. Rhinitis and anosmia were protective against LDCT abnormalities.

Identifiants

pubmed: 33201409
doi: 10.1186/s13244-020-00939-7
pii: 10.1186/s13244-020-00939-7
pmc: PMC7670109
doi:

Types de publication

Journal Article

Langues

eng

Pagination

117

Commentaires et corrections

Type : ErratumIn

Références

J Am Geriatr Soc. 2020 May;68(5):926-929
pubmed: 32255507
Acad Radiol. 2020 May;27(5):603-608
pubmed: 32204987
AJR Am J Roentgenol. 2020 Aug;215(2):338-343
pubmed: 32181672
Invest Radiol. 2020 Jun;55(6):327-331
pubmed: 32118615
J Clin Med. 2020 May 18;9(5):
pubmed: 32443442
Eur Radiol. 2020 Aug;30(8):4407-4416
pubmed: 32215691
Travel Med Infect Dis. 2020 Mar - Apr;34:101624
pubmed: 32179125
J Microbiol Immunol Infect. 2020 Jun;53(3):404-412
pubmed: 32173241
Radiol Cardiothorac Imaging. 2020 Mar 17;2(2):e200110
pubmed: 33778566
Travel Med Infect Dis. 2020 Jul - Aug;36:101632
pubmed: 32205269
Eur Radiol. 2020 Aug;30(8):4356-4357
pubmed: 32193637
Eur J Radiol. 2020 May;126:108956
pubmed: 32199142
Eur J Nucl Med Mol Imaging. 2020 May;47(5):1275-1280
pubmed: 32107577
Radiographics. 2004 Mar-Apr;24(2):553-63
pubmed: 15026600
Thromb Res. 2020 Sep;193:166-169
pubmed: 32707275
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Diabetes Metab Res Rev. 2020 Mar 31;:e3319
pubmed: 32233013
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Lancet Infect Dis. 2020 Apr;20(4):425-434
pubmed: 32105637
Radiology. 2020 Jun;295(3):200463
pubmed: 32077789
Medicine (Baltimore). 2016 Jun;95(26):e4003
pubmed: 27368011
Eur Radiol. 2020 Aug;30(8):4381-4389
pubmed: 32193638
J Thorac Imaging. 2010 Feb;25(1):68-75
pubmed: 20160606
Radiology. 2020 Aug;296(2):E97-E104
pubmed: 32339082
Intensive Care Med. 2020 Jun;46(6):1089-1098
pubmed: 32367170
J Biomed Phys Eng. 2019 Feb 01;9(1):127-132
pubmed: 30881942
Radiology. 2020 Sep;296(3):E189-E191
pubmed: 32324102
Aging (Albany NY). 2020 Apr 8;12(7):6049-6057
pubmed: 32267833
Chest. 2005 Jun;127(6):2119-24
pubmed: 15947329
Eur Radiol. 2020 Dec;30(12):6808-6817
pubmed: 32623505
Eur Radiol. 2020 Jun;30(6):3266-3267
pubmed: 32072255
Nat Microbiol. 2020 Apr;5(4):536-544
pubmed: 32123347
J Thorac Dis. 2019 Mar;11(3):972-986
pubmed: 31019788
Radiology. 2020 May;295(2):E3
pubmed: 32142398
Radiology. 2008 Mar;246(3):697-722
pubmed: 18195376
N Engl J Med. 2020 Feb 20;382(8):692-694
pubmed: 31978293
Respirology. 2003 Nov;8 Suppl:S15-9
pubmed: 15018128
Radiol Cardiothorac Imaging. 2020 Mar 30;2(2):e200047
pubmed: 33778560
AJR Am J Roentgenol. 2011 Nov;197(5):1088-95
pubmed: 22021500

Auteurs

Maxime Castelli (M)

Radiology Department, La Timone Hospital, Assistance Publique Des Hôpitaux de Marseille, 264 Rue Saint Pierre, 13005, Marseille 05, France.

Arnaud Maurin (A)

Radiology Department, La Timone Hospital, Assistance Publique Des Hôpitaux de Marseille, 264 Rue Saint Pierre, 13005, Marseille 05, France.

Axel Bartoli (A)

Radiology Department, La Timone Hospital, Assistance Publique Des Hôpitaux de Marseille, 264 Rue Saint Pierre, 13005, Marseille 05, France.
UMR 7339, CNRS, CRMBM-CEMEREM (Centre de Résonance Magnétique Biologique et Médicale - Centre d'Exploration Métaboliques par Résonance Magnétique), Assistance Publique - Hôpitaux de Marseille, Aix-Marseille Université, 13385, Marseille, France.

Michael Dassa (M)

Radiology Department, La Timone Hospital, Assistance Publique Des Hôpitaux de Marseille, 264 Rue Saint Pierre, 13005, Marseille 05, France.

Baptiste Marchi (B)

Radiology Department, La Timone Hospital, Assistance Publique Des Hôpitaux de Marseille, 264 Rue Saint Pierre, 13005, Marseille 05, France.

Julie Finance (J)

IHU-Méditerranée Infection, Marseille, France.

Jean-Christophe Lagier (JC)

IHU-Méditerranée Infection, Marseille, France.
IRD, APHM, Aix Marseille Univ, MEPHI, Marseille, France.

Matthieu Million (M)

IHU-Méditerranée Infection, Marseille, France.
IRD, APHM, Aix Marseille Univ, MEPHI, Marseille, France.

Philippe Parola (P)

IHU-Méditerranée Infection, Marseille, France.
IRD, APHM, Aix Marseille Univ, VITROME, Marseille, SSA, France.

Philippe Brouqui (P)

IHU-Méditerranée Infection, Marseille, France.
IRD, APHM, Aix Marseille Univ, MEPHI, Marseille, France.

Didier Raoult (D)

IHU-Méditerranée Infection, Marseille, France.
IRD, APHM, Aix Marseille Univ, MEPHI, Marseille, France.

Sebastien Cortaredona (S)

IHU-Méditerranée Infection, Marseille, France.
IRD, APHM, Aix Marseille Univ, VITROME, Marseille, SSA, France.

Alexis Jacquier (A)

Radiology Department, La Timone Hospital, Assistance Publique Des Hôpitaux de Marseille, 264 Rue Saint Pierre, 13005, Marseille 05, France.
UMR 7339, CNRS, CRMBM-CEMEREM (Centre de Résonance Magnétique Biologique et Médicale - Centre d'Exploration Métaboliques par Résonance Magnétique), Assistance Publique - Hôpitaux de Marseille, Aix-Marseille Université, 13385, Marseille, France.

Jean-Yves Gaubert (JY)

Radiology Department, La Timone Hospital, Assistance Publique Des Hôpitaux de Marseille, 264 Rue Saint Pierre, 13005, Marseille 05, France.
LIIE, Aix Marseille Univ, Marseille, France.
CERIMED, Aix Marseille Univ, Marseille, France.

Paul Habert (P)

Radiology Department, La Timone Hospital, Assistance Publique Des Hôpitaux de Marseille, 264 Rue Saint Pierre, 13005, Marseille 05, France. Paul.habert@ap-hm.fr.
LIIE, Aix Marseille Univ, Marseille, France. Paul.habert@ap-hm.fr.
CERIMED, Aix Marseille Univ, Marseille, France. Paul.habert@ap-hm.fr.

Classifications MeSH